Associations - EGFR exon 19 deletion + EGFR T790M + EGFR C797S + CTNNB1 exon 3 mutation

BIOMARKER:

EGFR exon 19 deletion + EGFR T790M + EGFR C797S + CTNNB1 exon 3 mutation

Entrez ID:

Related biomarkers:

‹

›

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

EGFR exon 19 deletion + EGFR T790M + EGFR C797S + CTNNB1 exon 3 mutation EGFR exon 19 deletion + EGFR T790M + EGFR C797S + CTNNB1 exon 3 mutation	Lung Adenocarcinoma LUAD	gefitinib + osimertinib Resistant: C4 – Case Studies gefitinib + osimertinib Resistant : C4
EGFR exon 19 deletion + EGFR T790M + EGFR C797S + CTNNB1 exon 3 mutation EGFR exon 19 deletion + EGFR T790M + EGFR C797S + CTNNB1 exon 3 mutation	Lung Adenocarcinoma LUAD	icotinib Resistant: C4 – Case Studies icotinib Resistant : C4
EGFR exon 19 deletion + EGFR T790M + EGFR C797S + CTNNB1 exon 3 mutation EGFR exon 19 deletion + EGFR T790M + EGFR C797S + CTNNB1 exon 3 mutation	Lung Adenocarcinoma LUAD	bevacizumab + osimertinib Resistant: C4 – Case Studies bevacizumab + osimertinib Resistant : C4
EGFR exon 19 deletion + EGFR T790M + EGFR C797S + CTNNB1 exon 3 mutation EGFR exon 19 deletion + EGFR T790M + EGFR C797S + CTNNB1 exon 3 mutation	Lung Adenocarcinoma LUAD	bevacizumab + icotinib Resistant: C4 – Case Studies bevacizumab + icotinib Resistant : C4